BeyondSpring Inc. Stock

Equities

BYSI

KYG108301006

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
1.91 USD +6.11% Intraday chart for BeyondSpring Inc. -8.61% +112.22%
Sales 2021 1.35 Sales 2022 1.35 Capitalization 73.18M
Net income 2021 -64M Net income 2022 -33M EV / Sales 2021 80,326,725 x
Net cash position 2021 68.79M Net cash position 2022 32.31M EV / Sales 2022 30,256,712 x
P/E ratio 2021
-2.75 x
P/E ratio 2022
-2.21 x
Employees 73
Yield 2021 *
-
Yield 2022
-
Free-Float 73.36%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on BeyondSpring Inc.

1 day+6.11%
1 week-8.61%
Current month-46.50%
1 month-38.78%
3 months+117.05%
6 months+91.00%
Current year+112.22%
More quotes
1 week
1.76
Extreme 1.76
2.07
1 month
1.76
Extreme 1.76
3.75
Current year
0.78
Extreme 0.7777
4.00
1 year
0.65
Extreme 0.6534
4.00
3 years
0.54
Extreme 0.542
33.00
5 years
0.54
Extreme 0.542
33.00
10 years
0.54
Extreme 0.542
48.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 12-12-31
Chief Tech/Sci/R&D Officer 80 15-05-31
Members of the board TitleAgeSince
Director/Board Member 56 18-01-01
Chief Executive Officer 53 12-12-31
Director/Board Member 55 16-10-12
More insiders
Date Price Change Volume
24-04-19 1.91 +6.11% 80,217
24-04-18 1.8 -2.70% 55,502
24-04-17 1.85 +2.78% 104,609
24-04-16 1.8 +2.27% 37,542
24-04-15 1.76 -15.79% 75,265

Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT

More quotes
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
More about the company